IFF | February 17, 2022
IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry.
Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplements. Using state-of-the-art processes and equipment, HWP manufactures custom formulations, and delivers encapsulation and packaging to meet the industries’ more exacting requirements for probiotic products. With over 165,000 ft2 (15,328 m2) of manufacturing space, the company generated approximately $100 million in annual revenue in 2021 and employed over 225 people who will continue with the company after the sale.
The acquisition will bring formulation and finished format capabilities to IFF’s Health & Biosciences probiotics, natural extracts and botanicals businesses, allowing for innovation in custom formulation and combination products through joint capabilities.
“Today’s announcement is driven by our commitment to enhance long-term value to our partners and customers. Producing thousands of unique and complex formulations for the industry’s most trusted brands, Health Wright Products formulation and finished format abilities will allow us to develop new and customized solutions and formats for a broad base of customers,”
Simon Herriott, President, IFF’s Health & Biosciences division
“We look forward to joining IFF’s Health & Biosciences division. Health Wright Products best-in-class quality manufacturing and formulation capabilities, combined with the strong biotech innovation pipeline of IFF’s Health & Biosciences, is an exciting proposition for our customers and employees,” said Mark Wright, President, Health Wright Products.
The sale is expected to close in the first quarter of 2022, subject to customary closing conditions, and regulatory clearances. Financial terms of the deal have not been disclosed.
About Health Wright Products, LLC.
At Health Wright Products, a contract manufacture of dietary supplements, Quality, Service and Value have been the driving principles in our commitment to exceeding customers’ expectations. We partner with brands committed to the same driving principles for themselves and their customers. As a global industry leader, we leverage innovation, technology, experience and capacity to offer better solutions to current and emerging products. Providing better health by Encapsulating Excellence.
About IFF’s Health & Biosciences division
Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Biosciences division is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. IFF’s Health & Biosciences division works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions.
Welcome to IFF
At IFF an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves.
CELL AND GENE THERAPY
CardioGenomic | March 23, 2022
Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade testing, and improve clinical outcomes.
The companies forming this coalition believe in extensive clinical utility of cardiogenomic testing. Their combined efforts to increase awareness and utilization of cardiogenomic testing will show the positive outcomes genetic testing can have on patients."
Melissa Dempsey, genetic counselor at Illumina and CGTA chairwoman.
Genomic testing in cardiology is a powerful tool that can identify those at-risk for specific cardiac conditions, such as arrhythmias, cardiomyopathies, and congenital heart malformations. According to the American Heart Association, "genetic testing is informative and useful for the clinical management of various inherited cardiovascular diseases such as cardiomyopathies, arrhythmic disorders, thoracic aortic aneurysms and dissections, and familial hypercholesterolemia."1 Sudden cardiac arrest can often be the first symptom of an inherited cardiac condition.2 The Sudden Arrhythmia Death Syndromes (SADS) Foundation reports that up to 49% of victims of sudden cardiac death had a significant family history that should have triggered diagnostic testing, and cascade genetic testing reveals an average of 8.9 additional affected family members.3
Genetic testing is one of the essential steps in the diagnosis and treatment of families with SADS conditions."
Alice Lara, president of the SADS Foundation.
Despite evidence and major professional society recommendations, utilization and awareness of cardiogenomic testing remains low. CGTA will strive to inform healthcare providers about the current guidelines for the appropriate use of genetic testing in cardiology. Working with key stakeholders, CGTA will identify logistical barriers to testing and develop educational resources to address these barriers for providers and for the public.
Sequence Bio | April 08, 2022
Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.
We are delighted to enter this collaboration agreement with Sequence Bio to further accelerate LEO Pharma's ambition to identify novel dermatologic drug targets, LEO Pharma is relentlessly committed to making pioneering advances in dermatology research and bringing new treatments to patients faster."
Thorsten Thormann, Vice President of Research & Early Development in LEO Pharma.
We are excited to work with LEO Pharma on their mission to positively impact millions of lives through medical dermatology, This collaboration aligns with our strategic priorities to expand the potential of our discovery platform to power life-changing medicines in areas of unmet medical need across the globe."
Dr. Richard Leach, Chief Strategy Officer of Sequence Bio.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of EUR 1,339 million.
About Sequence Bio
Sequence Bio is a commercial-stage biotechnology company based in Newfoundland and Labrador, Canada. The company's platform leverages Newfoundland's founder effect to power discovery cohorts for novel target identification across numerous disease indications. Sequence Bio collaborates with the people of Newfoundland and Labrador, and partners with leading pharma and biotech to help accelerate the development of new medicines for global unmet medical need.
Indica Labs | May 13, 2022
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Indica Labs, a leading provider of computational pathology software and services, today announced a partnership to co-market an end-to-end solution that combines Lunaphore's flagship COMET™ spatial biology platform and Indica's HALO® and HALO AI™ digital pathology image analysis software.
Lunaphore's COMET™ platform provides superior multiplex staining and image acquisition capabilities facilitating the automated detection of up to 40 separate spatial markers per tissue slide without human intervention. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free antibodies and is designed to provide researchers with flexibility for their workflow. COMET™ has a wide range of research applications across immuno-oncology, neuroscience, and infectious diseases.
Indica Labs' industry-leading HALO® and HALO AITM software enable fast, AI-based quantitative analysis of whole slide images. In combination with the COMET™ platform, the HALO Highplex FL module allows researchers to quantify an unlimited number of fluorescent markers and cell phenotypes defined by their biomarker expression. HALO Spatial Analysis and HALO AI deep learning classifiers are used in combination with Highplex FL to explore the distribution and spatial relationships between different cell phenotypes in the context of the tissue, such as tumor and immune cells. This additional spatial data is particularly important in immuno-oncology and neuroscience disease research.
We are excited to partner with Lunaphore to address the growing needs of our research customers for highly multiplexed assays, Combining Lunaphore's superior multiplexing technologies upstream with our powerful AI-based analysis downstream, together we provide a streamlined workflow for high dimensional imaging and image analysis."
Steven Hashagen, CEO of Indica Labs.
Our partnership with Indica Labs is another key aspect of our strategy to combine our COMET™ technology with industry-leading image analysis technologies, Indica Labs' solutions are used by a large set of researchers in the field, thanks to their ease of use and analysis capabilities. Combining Indica's solutions with the class-leading capabilities of COMET™ will help us pursue our shared goal of making tissue image analysis easier and more accessible to labs around the world."
Deborah Heintze, Chief Marketing Officer of Lunaphore.
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.
About Indica Labs
Indica Labs is the world's leading provider of computational pathology software and image analysis services. Our flagship HALO® and HALO AI™ platform facilitates quantitative evaluation of digital pathology images. HALO Link™ facilitates research-focused image management and collaboration while HALO AP® enables collaborative clinical case review. Our Pharma Services team leverages all our image analysis platforms to partner with you to advance tissue-based research, clinical trials, and diagnostics.